News Protalix BioTherapeutics, Inc.

Stocks

PLX

US74365A3095

Pharmaceuticals

Real-time Estimate Cboe BZX 01:36:25 04/11/2026 am IST			5-day change	1st Jan Change
2.535 ^USD	-0.98%		+0.40%	+41.11%

16/09	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
12/08	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

All News

Mentions Relevance

05:21pm	Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026	PR
26/10	Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference	PR
16/09	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08/09	Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences	PR
12/08	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
12/08	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
12/08	Protalix: Q2 Earnings Snapshot	AQ
12/08	Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results	PR
12/08	Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026	CI
05/08	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026	PR
13/05	Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
13/05	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/05	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)	PU
13/05	Protalix: Q1 Earnings Snapshot	AQ
13/05	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results	PR
13/05	Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026	CI
06/05	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026	PR
19/03	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa	CI
18/03	Top Midday Decliners	MT
18/03	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03	Protalix BioTherapeutics, Inc., 2025 Earnings Call, Mar 18, 2026
18/03	Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026	CI
18/03	Protalix Biotherapeutics reports fiscal year 2025 financial and business results	RE
18/03	Protalix: Q4 Earnings Snapshot	AQ
18/03	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results	PR